This is a HIA partner technology
Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.
Mitotic kinesins are motor proteins required to facilitate proper cell division (mitosis). Recent studies by Dr. Rosenfeld and his team have shown that one of these kinesins, Eg5, is up-regulated in tumor cells from human glioblastomas.
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. Dr. Rich and his team have developed aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells, identified by screening a large pool of randomly generated aptamers to obtain a discrete set of them that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma.
The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement.
Tumors adapt their phenotypes during growth and in response to therapies through
dynamic changes in cellular processes. The connexin family proteins enable such dynamic changes during development and their dysregulation leads to disease states. The cellular networks formed by connexins have been reported to exhibit tumor-suppressive functions, including in triple-negative breast cancer (TNBC).
Mantle cell lymphoma (MCL) is incurable using current standard therapeutic regimens. Additionally, there are relatively few cell lines and mouse models to support drug discovery and development efforts.
Integration of high-throughput radiation survival profiling with large-scale cancer genomic data suggests AR expression is associated with therapeutic resistance in breast cancer. Our analysis nominates anti-androgen therapies, which are commercially available and currently in clinical use in prostate and breast cancer, as therapeutic sensitizers in select AR positive breast cancer.
The invention includes a diagnostic and prognostic means of using hyper-methylation analysis of the promoter region of KLLN encoding KILLIN, a novel tumor suppressor gene, whose transcriptional downregulation identifies patients who have heightened risk for breast and renal neoplasms when presenting with a PTEN mutation negative, Cowden Syndrome/Cowden-like syndrome (CS/CSL) background.
The technology is a diagnostic tool that assesses an actionable biomarker for treatment selection in the prostate cancer care continuum.
The invention includes a means of using mutational variants in the succinate dehydrogenase gene (SDH) for diagnosis and prognosis of those who have heightened risk for breast, thyroid and renal neoplasms when presenting with a PTEN mutation negative, Cowden Syndrome/Cowden-like syndrome (CS/CSL) germline background.